Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [18]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 19178-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#19178-1-AP, RRID:AB_10926385
- Product name
- PSMB5 antibody
- Antibody type
- Polyclonal
- Description
- PSMB5 antibody (Cat. #19178-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Ixazomib triggers autophagic degradation of MUC5AC/integrin-β4 and inhibits non-small cell lung cancer progression.
Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery.
Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway.
Immunoproteasome deficiency results in age-dependent development of epilepsy.
Using protein turnover assay to explore the drug mechanism of Carfilzomib.
Discovery of novel 20S proteasome subunit β5 PROTAC degraders as potential therapeutics for pharyngeal carcinoma and Bortezomib-resistant multiple myeloma.
PTEN status determines therapeutic vulnerability to celastrol in cholangiocarcinoma.
Development and validation of a ubiquitin-proteasome system gene signature for prognostic prediction and immune microenvironment evaluation in hepatocellular carcinoma.
WDR45 mutation dysregulates iron homeostasis by promoting the chaperone-mediated autophagic degradation of ferritin heavy chain in an ER stress/p38 dependent mechanism.
Cascade-Activated AIEgen-Peptide Probe for Noninvasively Monitoring Chymotrypsin-like Activity of Proteasomes in Cancer Cells.
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap.
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
Melatonin inhibits angiotensin II-induced atrial fibrillation through preventing degradation of Ang II Type I Receptor-Associated Protein (ATRAP).
Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung cancer A549 cells.
Selective Inhibition of the Immunoproteasome β5i Prevents PTEN Degradation and Attenuates Cardiac Hypertrophy.
Cancer vulnerabilities unveiled by genomic loss.
Appadurai MI, Alsafwani ZW, Chaudhary S, Shah A, Somavarapu P, Dooshety SN, Kubicek BS, Batra SK, Lakshmanan I, Ganti AK
Cancer letters 2026 May 1;645:218333
Cancer letters 2026 May 1;645:218333
Targeting PSMB5-induced PANoptosis in bladder cancer: multi-omics insights and TCM candidate discovery.
Chang Z, Wang J, Cao J, Fan X, Li K, Wang C, Zhang Y, Wang L, Yang J, Chen S, Yang L
Frontiers in immunology 2025;16:1656682
Frontiers in immunology 2025;16:1656682
Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway.
Wu HQ, Qin RC, Li WJ, Liu JN, Deng C, Zheng ZH, Zheng JP, Liu Y, Meng YF, Tang C, Tan HM, Duan FF, Tang Y, Xiao F, Lu LW, Dai XY, Ma KY
Acta pharmacologica Sinica 2025 Jul;46(7):2041-2055
Acta pharmacologica Sinica 2025 Jul;46(7):2041-2055
Immunoproteasome deficiency results in age-dependent development of epilepsy.
Leister H, Krause FF, Gil B, Prus R, Prus I, Hellhund-Zingel A, Mitra M, Da Rosa Gerbatin R, Delanty N, Beausang A, Brett FM, Farrell MA, Cryan J, O'Brien DF, Henshall DC, Helmprobst F, Pagenstecher A, Steinhoff U, Visekruna A, Engel T
Brain communications 2024;6(1):fcae017
Brain communications 2024;6(1):fcae017
Using protein turnover assay to explore the drug mechanism of Carfilzomib.
Tao Y, Ding X, Jia C, Wang C, Li C
Acta biochimica et biophysica Sinica 2024 Jul 8;57(2):209-222
Acta biochimica et biophysica Sinica 2024 Jul 8;57(2):209-222
Discovery of novel 20S proteasome subunit β5 PROTAC degraders as potential therapeutics for pharyngeal carcinoma and Bortezomib-resistant multiple myeloma.
Wang S, Li Z, Ma S, Zhang S, Guo S, Ma Z, Du L, Li M
Bioorganic chemistry 2024 Dec;153:107801
Bioorganic chemistry 2024 Dec;153:107801
PTEN status determines therapeutic vulnerability to celastrol in cholangiocarcinoma.
Pan YF, Zhong L, Wang M, Jiang TY, Lin YK, Chen YB, Li X, Hu HP, Zhou HB, Yan HZ, Dong LW
Phytomedicine : international journal of phytotherapy and phytopharmacology 2024 Aug;131:155790
Phytomedicine : international journal of phytotherapy and phytopharmacology 2024 Aug;131:155790
Development and validation of a ubiquitin-proteasome system gene signature for prognostic prediction and immune microenvironment evaluation in hepatocellular carcinoma.
Liu ZY, Li YH, Zhang QK, Li BW, Xin L
Journal of cancer research and clinical oncology 2023 Nov;149(14):13363-13382
Journal of cancer research and clinical oncology 2023 Nov;149(14):13363-13382
WDR45 mutation dysregulates iron homeostasis by promoting the chaperone-mediated autophagic degradation of ferritin heavy chain in an ER stress/p38 dependent mechanism.
Xiong Q, Sun H, Xing W, Li X, Chen G, Zhao Z, Wu C, Li P
Free radical biology & medicine 2023 May 20;201:89-97
Free radical biology & medicine 2023 May 20;201:89-97
Cascade-Activated AIEgen-Peptide Probe for Noninvasively Monitoring Chymotrypsin-like Activity of Proteasomes in Cancer Cells.
Jiao Q, Zheng Y, Pei S, Luo X, Wu X, Xu K, Zhong W
Analytical chemistry 2023 Jun 13;95(23):9097-9106
Analytical chemistry 2023 Jun 13;95(23):9097-9106
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
Luo H, Feng Y, Wang F, Lin Z, Huang J, Li Q, Wang X, Liu X, Zhai X, Gao Q, Li L, Zhang Y, Wen J, Zhang L, Niu T, Zheng Y
Cancer letters 2023 Jul 1;565:216218
Cancer letters 2023 Jul 1;565:216218
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
Bai Y, Zhou L, Zhang C, Guo M, Xia L, Tang Z, Liu Y, Deng S
Oncogene 2023 Dec;42(49):3605-3618
Oncogene 2023 Dec;42(49):3605-3618
miR-125a-5p/miR-125b-5p contributes to pathological activation of angiotensin II-AT1R in mouse distal convoluted tubule cells by the suppression of Atrap.
Hirota K, Yamashita A, Abe E, Yamaji T, Azushima K, Tanaka S, Taguchi S, Tsukamoto S, Wakui H, Tamura K
The Journal of biological chemistry 2023 Dec;299(12):105478
The Journal of biological chemistry 2023 Dec;299(12):105478
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, Snaurova R, Radhakrishnan D, Turi M, Chyra Z, Popkova T, Venglar O, Hrdinka M, Hajek R, Simicek M
Nature communications 2022 Nov 10;13(1):6820
Nature communications 2022 Nov 10;13(1):6820
Melatonin inhibits angiotensin II-induced atrial fibrillation through preventing degradation of Ang II Type I Receptor-Associated Protein (ATRAP).
Xie X, Shen TT, Bi HL, Su ZL, Liao ZQ, Zhang Y, Shi L, Xia YL
Biochemical pharmacology 2022 Aug;202:115146
Biochemical pharmacology 2022 Aug;202:115146
Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung cancer A549 cells.
Yu H, Kim YM, Cho M
Journal of Cancer 2020;11(15):4495-4509
Journal of Cancer 2020;11(15):4495-4509
Selective Inhibition of the Immunoproteasome β5i Prevents PTEN Degradation and Attenuates Cardiac Hypertrophy.
Xie X, Wang HX, Li N, Deng YW, Bi HL, Zhang YL, Xia YL, Li HH
Frontiers in pharmacology 2020;11:885
Frontiers in pharmacology 2020;11:885
Cancer vulnerabilities unveiled by genomic loss.
Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, Tsherniak A, Besche HC, Rosenbluh J, Shehata S, Cowley GS, Weir BA, Goldberg AL, Mesirov JP, Root DE, Bhatia SN, Beroukhim R, Hahn WC
Cell 2012 Aug 17;150(4):842-54
Cell 2012 Aug 17;150(4):842-54
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- L02 cells were subjected to SDS PAGE followed by western blot with 19178-1-AP(PSMB5 antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human breast cancer using 19178-1-AP(PSMB5 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The PSMB5 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human PSMB5. This antibody recognizes human,mouse,rat antigen. The PSMB5 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
